Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Polycystic Ovary Syndrome 3Peripheral Nervous System Diseases 3Ovarian Neoplasms 3Lung Neoplasms 3Carcinoma, Hepatocellular 3Stomatitis 2Stomach Neoplasms 2Pseudomyxoma Peritonei 2Ototoxicity 2Neurofibromatosis 1 2Neoplasms 2Liver Neoplasms 2Hearing Loss 2Head and Neck Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Weight Loss 1Ulcer 1Tongue Neoplasms 1Tomaculous neuropathy 1Thrombocythemia, Essential 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Renal Insufficiency, Chronic 1Renal Artery Obstruction 1Radiation-Induced Mucositis 1Radiation Pneumonitis 1Pulmonary Embolism 1Primary Myelofibrosis 1Primary Graft Dysfunction 1

Interventions

sodium thiosulfate 2ebselen 2Ankle Brachial Index 2Acetylcysteine 2Tomography, X-Ray Computed 1Sodium Chloride 1Saline Solution 1Ringer's Lactate 1Platinum 1Ofloxacin 1Magnetic Resonance Spectroscopy 1Magnetic Resonance Imaging 1Hyaluronic Acid 1Hearing Tests 1Hearing 1Ear Protective Devices 1Cisplatin 1Audiometry, Pure-Tone 1Atorvastatin 1Acoustic Impedance Tests 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Hearing Loss × Acetylcysteine × Clear all
NCT04291209 2023-09-06

Intratympanic N-Acetylcysteine for Prevention of Cisplatin-induced Ototoxicity.

Sunnybrook Health Sciences Centre

Phase 1/2 Unknown
80 enrolled

Deafness, Ear Diseases, Hearing Loss, Sensorineural, Hearing Loss

NCT02094625 2023-04-18

NAC to Prevent Cisplatin-induced Hearing Loss

Children's Hospital Los Angeles

Phase 1 Completed
52 enrolled
GastrointestinalSarcoma

Liver Neoplasms, Osteosarcoma, Neuroectodermal Tumors, Primitive, Hearing Loss

Data powered by HemOnc (CC BY 4.0) Colophon âš¡